Type 3 Pharma - Cancer therapy based on bacterial protein delivery

• Unité de recherche: INNOSUISSE
• Numéro de projet: 18026.1 PFLS-LS
• Titre du projet anglais: Type 3 Pharma - Cancer therapy based on bacterial protein delivery

Description succincte (Allemand)

Type 3 Pharma - Therapie von Krebs mit genetisch modifizierten Bakterien

Description succincte (Anglais)

Type 3 Pharma - Cancer therapy based on bacterial protein delivery

Résumé des résultats (Abstract) (Allemand)

Bacteria offer an ideal vehicle to deliver cargo to cancer cells as they preferentially grow within solid tumors.|We have developed a technology based on a bacterial nano-needle to directly inject proteins into cancer cells|and have obtained very promising results in delivering toxic proteins to cancer cells. Our aim is to optimize this|system and to validate its efficacy in murine models of cancer. Our vision is to bring this novel treatment|strategy into clinicial practice.

Résumé des résultats (Abstract) (Anglais)

Bacteria offer an ideal vehicle to deliver cargo to cancer cells as they preferentially grow within solid tumors.|We have developed a technology based on a bacterial nano-needle to directly inject proteins into cancer cells|and have obtained very promising results in delivering toxic proteins to cancer cells. Our aim is to optimize this|system and to validate its efficacy in murine models of cancer. Our vision is to bring this novel treatment|strategy into clinicial practice.